35 results on '"Rimel, Bobbie"'
Search Results
2. Sexual orientation and gender identity inequities in cervical cancer screening by race and ethnicity
- Author
-
Lin, Emmeline, Sleboda, Patrycja, Rimel, Bobbie J., Chen, Jarvis T., Hernandez, Diana V., and Datta, Geetanjali D.
- Published
- 2024
- Full Text
- View/download PDF
3. Inequities in colorectal and breast cancer screening: At the intersection of race/ethnicity, sexuality, and gender
- Author
-
Lin, Emmeline, Sleboda, Patrycja, Rimel, Bobbie J., and Datta, Geetanjali D.
- Published
- 2023
- Full Text
- View/download PDF
4. The association of black race with receipt of hysterectomy and survival in low-risk endometrial cancer
- Author
-
Taylor, Kristin N., Li, Andrew, Manuel, Michael, Rimel, Bobbie Jo, and Kim, Kenneth H.
- Published
- 2023
- Full Text
- View/download PDF
5. Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations
- Author
-
Rimel, Bobbie J., Crane, Erin K., Hou, June, Nakayama, John, MacDonald, Jennifer, Lutz, Kathleen, Makker, Vicky, and O'Cearbhaill, Roisin E.
- Published
- 2023
- Full Text
- View/download PDF
6. DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers
- Author
-
Gull, Nicole, Jones, Michelle R., Peng, Pei-Chen, Coetzee, Simon G., Silva, Tiago C., Plummer, Jasmine T., Reyes, Alberto Luiz P., Davis, Brian D., Chen, Stephanie S., Lawrenson, Kate, Lester, Jenny, Walsh, Christine, Rimel, Bobbie J., Li, Andrew J., Cass, Ilana, Berg, Yonatan, Govindavari, John-Paul B., Rutgers, Joanna K. L., Berman, Benjamin P., Karlan, Beth Y., and Gayther, Simon A.
- Published
- 2022
- Full Text
- View/download PDF
7. NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
- Author
-
Rimel, Bobbie J., Enserro, Danielle, Bender, David P., Jackson, Camille Gunderson, Tan, Annie, Alluri, Nitya, Borowsky, Mark, Moroney, John, Hendrickson, Andrea Wahner, Backes, Floor, Swisher, Elizabeth, Powell, Matthew, and MacKay, Helen
- Subjects
- *
ENDOMETRIAL cancer , *OLAPARIB , *METASTASIS , *CANCER patients , *PROGRESSION-free survival - Abstract
Purpose: This paper reports the efficacy of the poly (ADP‐ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer. Methods: This was open‐label, randomized, phase 2 trial (NCT03660826). Eligible patients had recurrent endometrial cancer, received at least one (<3) prior lines of chemotherapy, and were Eastern Cooperative Oncology Group performance status 0 to 2. Patients were randomly assigned (1:1:1), stratified by histology (serous vs. other) to receive cediranib alone (reference arm), olaparib, or olaparib and cediranib for 28‐day cycles until progression or unacceptable toxicity. The primary end point was progression‐free survival in the intention‐to‐treat population. Homologous repair deficiency was explored using the BROCA‐GO sequencing panel. Results: A total of 120 patients were enrolled and all were included in the intention‐to‐treat analysis. Median age was 66 (range, 41–86) years and 47 (39.2%) had serous histology. Median progression‐free survival for cediranib was 3.8 months compared with 2.0 months for olaparib (hazard ratio, 1.45 [95% CI, 0.91‐2.3] p =.935) and 5.5 months for olaparib/cediranib (hazard ratio, 0.7 [95% CI, 0.43–1.14] p =.064). Four patients receiving the combination had a durable response lasting more than 20 months. The most common grade 3/4 toxicities were hypertension in the cediranib (36%) and olaparib/cediranib (33%) arms, fatigue (20.5% olaparib/cediranib), and diarrhea (17.9% cediranib). The BROCA‐GO panel results were not associated with response. Conclusion: The combination of cediranib and olaparib demonstrated modest clinical efficacy; however, the primary end point of the study was not met. The combination was safe without unexpected toxicity. Randomized study of cediranib compared with olaparib and the combination for advanced or recurrent endometrial cancer demonstrated progression‐free survival of 3.8, 2.0, and 5.5 months respectively. The treatment toxicities were manageable but the study did not meet its primary end point. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer
- Author
-
Matsuo, Koji, Cripe, James C., Kurnit, Katherine C., Kaneda, Michiko, Garneau, Audrey S., Glaser, Gretchen E., Nizam, Aaron, Schillinger, Rachel M., Kuznicki, Michelle L., Yabuno, Akira, Yanai, Shiori, Garofalo, Denise M., Suzuki, Jiro, St. Laurent, Jessica D., Yen, Ting-Tai, Liu, Annie Y., Shida, Masako, Kakuda, Mamoru, Oishi, Tetsuro, Nishio, Shin, Marcus, Jenna Z., Adachi, Sosuke, Kurokawa, Tetsuji, Ross, Malcolm S., Horowitz, Max P., Johnson, Marian S., Kim, Min K., Melamed, Alexander, Machado, Karime K., Yoshihara, Kosuke, Yoshida, Yoshio, Enomoto, Takayuki, Ushijima, Kimio, Satoh, Shinya, Ueda, Yutaka, Mikami, Mikio, Rimel, Bobbie J., Stone, Rebecca L., Growdon, Whitfield B., Okamoto, Aikou, Guntupalli, Saketh R., Hasegawa, Kosei, Shahzad, Mian M.K., Im, Dwight D., Frimer, Marina, Gostout, Bobbie S., Ueland, Frederick R., Nagao, Shoji, Soliman, Pamela T., Thaker, Premal H., Wright, Jason D., and Roman, Lynda D.
- Published
- 2019
- Full Text
- View/download PDF
9. Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study
- Author
-
Cerda, Victoria R, Lu, Diana, Scott, Marla, Kim, Kenneth H, Rimel, Bobbie Jo, and Kamrava, Mitchell
- Published
- 2022
- Full Text
- View/download PDF
10. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- Author
-
Moore, Kathleen N, Secord, Angeles Alvarez, Geller, Melissa A, Miller, David Scott, Cloven, Noelle, Fleming, Gini F, Wahner Hendrickson, Andrea E, Azodi, Masoud, DiSilvestro, Paul, Oza, Amit M, Cristea, Mihaela, Berek, Jonathan S, Chan, John K, Rimel, Bobbie J, Matei, Daniela E, Li, Yong, Sun, Kaiming, Luptakova, Katarina, Matulonis, Ursula A, and Monk, Bradley J
- Published
- 2019
- Full Text
- View/download PDF
11. Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting
- Author
-
Rimel, Bobbie J., Chase, Dana M., Perhanidis, Jessica, Ghazarian, Armen A., Du, Ella Xiaoyan, Wang, Travis, Song, Jinlin, Golembesky, Amanda K., Hurteau, Jean A., Kalilani, Linda, Salani, Ritu, and Monk, Bradley J.
- Published
- 2024
- Full Text
- View/download PDF
12. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study
- Author
-
Dixon-Suen, Suzanne C., Nagle, Christina M., Thrift, Aaron P., Pharoah, Paul D. P., Ewing, Ailith, Pearce, Celeste Leigh, Zheng, Wei, Australian Ovarian Cancer Study Group, Chenevix-Trench, Georgia, Fasching, Peter A., Beckmann, Matthias W., Lambrechts, Diether, Vergote, Ignace, Lambrechts, Sandrina, Van Nieuwenhuysen, Els, Rossing, Mary Anne, Doherty, Jennifer A., Wicklund, Kristine G., Chang-Claude, Jenny, Jung, Audrey Y., Moysich, Kirsten B., Odunsi, Kunle, Goodman, Marc T., Wilkens, Lynne R., Thompson, Pamela J., Shvetsov, Yurii B., Dörk, Thilo, Park-Simon, Tjoung-Won, Hillemanns, Peter, Bogdanova, Natalia, Butzow, Ralf, Nevanlinna, Heli, Pelttari, Liisa M., Leminen, Arto, Modugno, Francesmary, Ness, Roberta B., Edwards, Robert P., Kelley, Joseph L., Heitz, Florian, du Bois, Andreas, Harter, Philipp, Schwaab, Ira, Karlan, Beth Y., Lester, Jenny, Orsulic, Sandra, Rimel, Bobbie J., Kjær, Susanne K., Høgdall, Estrid, Jensen, Allan, Goode, Ellen L., Fridley, Brooke L., Cunningham, Julie M., Winham, Stacey J., Giles, Graham G., Bruinsma, Fiona, Milne, Roger L., Southey, Melissa C., Hildebrandt, Michelle A. T., Wu, Xifeng, Lu, Karen H., Liang, Dong, Levine, Douglas A., Bisogna, Maria, Schildkraut, Joellen M., Berchuck, Andrew, Cramer, Daniel W., Terry, Kathryn L., Bandera, Elisa V., Olson, Sara H., Salvesen, Helga B., Thomsen, Liv Cecilie Vestrheim, Kopperud, Reidun K., Bjorge, Line, Kiemeney, Lambertus A., Massuger, Leon F. A. G., Pejovic, Tanja, Bruegl, Amanda, Cook, Linda S., Le, Nhu D., Swenerton, Kenneth D., Brooks-Wilson, Angela, Kelemen, Linda E., Lubiński, Jan, Huzarski, Tomasz, Gronwald, Jacek, Menkiszak, Janusz, Wentzensen, Nicolas, Brinton, Louise, Yang, Hannah, Lissowska, Jolanta, Høgdall, Claus K., Lundvall, Lene, Song, Honglin, Tyrer, Jonathan P., Campbell, Ian, Eccles, Diana, Paul, James, Glasspool, Rosalind, Siddiqui, Nadeem, Whittemore, Alice S., Sieh, Weiva, McGuire, Valerie, Rothstein, Joseph H., Narod, Steven A., Phelan, Catherine, Risch, Harvey A., McLaughlin, John R., Anton-Culver, Hoda, Ziogas, Argyrios, Menon, Usha, Gayther, Simon A., Ramus, Susan J., Gentry-Maharaj, Aleksandra, Wu, Anna H., Pike, Malcolm C., Tseng, Chiu-Chen, Kupryjanczyk, Jolanta, Dansonka-Mieszkowska, Agnieszka, Budzilowska, Agnieszka, Rzepecka, Iwona K., Webb, Penelope M., and on behalf of the Ovarian Cancer Association Consortium
- Published
- 2018
- Full Text
- View/download PDF
13. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- Author
-
Mirza, Mansoor R., Monk, Bradley J., Herrstedt, Jørn, Oza, Amit M., Mahner, Sven, Redondo, Andrés, Fabbro, Michel, Ledermann, Jonathan A., Lorusso, Domenica, Vergote, Ignace, Ben-Baruch, Noa E., Marth, Christian, Mądry, Radoslaw, Christensen, René D., Berek, Jonathan S., Dørum, Anne, Tinker, Anna V., du Bois, Andreas, González-Martín, Antonio, Follana, Philippe, Benigno, Benedict, Rosenberg, Per, Gilbert, Lucy, Rimel, Bobbie J., Buscema, Joseph, Balser, John P., Agarwal, Shefali, and Matulonis, Ursula A.
- Published
- 2017
- Full Text
- View/download PDF
14. Current gaps and opportunities in screening, prevention, and treatment of cervical cancer.
- Author
-
Rimel, Bobbie J., Kunos, Charles A., Macioce, Nikeya, and Temkin, Sarah M.
- Subjects
- *
CERVICAL cancer , *MEDICAL screening , *HUMAN papillomavirus vaccines , *GENITAL warts , *CANCER treatment , *WOMEN'S health - Abstract
In their fiscal year 2021 reports, the US House and Senate Appropriations Committees requested that the National Institutes of Health (NIH) evaluate current research related to women's health and topics that include stagnant cervical cancer survival. In response, the NIH Office of Research on Women's Health, with input from women's health experts; members of the public; representatives from NIH institutes, centers, and offices; and members of the NIH Advisory Committee on Research on Women's Health, reviewed the public health needs and current NIH activities on cervical cancer. The Advancing NIH Research on the Health of Women: A 2021 Conference held in October 2021 reviewed these findings and allowed the identification of opportunities to strengthen research. In this review, the authors summarize public health needs related to cervical cancer and NIH activities in this realm. Cervical cancer has become a rare disease in the United States, yet significant portions of the US population remain under screened or unscreened for cervical cancer, human papillomavirus vaccination rates remain low, access to high‐quality treatment remains a challenge for many, and large inequities by race and ethnicity persist. Novel, inclusive, and intentional research is needed to produce improvements in cervical cancer survival within the United States. Mortality from cervical cancer is a direct reflection of resource distribution. Future research to decrease mortality must account for systemic failures to eradicate inequities in addition to the development of novel agents against this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Adnectin-Targeted Inhibitors: Rationale and Results
- Author
-
Sachdev, Esha, Gong, Jun, Rimel, Bobbie, and Mita, Monica
- Published
- 2015
- Full Text
- View/download PDF
16. Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy (2200)
- Author
-
Chase, Dana, Rimel, Bobbie, Perhanidis, Jessica, Ghazarian, Armen, Du, Ella Xiaoyan, Wang, Travis, Song, Jinlin, Golembesky, Amanda, Hurteau, Jean, Salani, Ritu, and Monk, Bradley
- Published
- 2023
- Full Text
- View/download PDF
17. Investigation of posttreatment NCCN surveillance adherence for patients with endometrial cancer who developed recurrence (1111)
- Author
-
Mayer, Christopher, O'Connor, Reed, Scott, Marla, Li, Andrew, Rimel, Bobbie, Taylor, Kristin, Manuel, Michael, and Kim, Kenneth
- Published
- 2023
- Full Text
- View/download PDF
18. Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers
- Author
-
Gangi, Alexandra, Cass, Ilana, Paik, Daniel, Barmparas, Galinos, Karlan, Beth, Dang, Catherine, Li, Andrew, Walsh, Christine, Rimel, Bobbie J., and Amersi, Farin F.
- Published
- 2014
- Full Text
- View/download PDF
19. P26 Mechanisms of response and resistance to epigenetic therapies in ovarian cancer
- Author
-
Huang, Dandi, Abassi, Forough, Modak, Maya, Ellis, Leigh, Rimel, Bobbie, Haro, Marcela, and Lawrenson, Kate
- Published
- 2023
- Full Text
- View/download PDF
20. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
- Author
-
Walsh, Christine S., Kamrava, Mitchell, Rogatko, Andre, Kim, Sungjin, Li, Andrew, Cass, Ilana, Karlan, Beth, and Rimel, Bobbie J.
- Subjects
ANTIMETABOLITES ,CISPLATIN ,OVARIAN cancer ,PEMBROLIZUMAB ,OVERALL survival ,PROGRESSION-free survival ,GEMCITABINE - Abstract
Objective: To evaluate the combination of pembrolizumab, cisplatin and gemcitabine in recurrent platinum-resistant ovarian cancer. Methods: Patients received six cycles of chemotherapy with gemcitabine and cisplatin on day 1 and day 8 of a 21-day treatment cycle. Pembrolizumab was administered on day 1 of cycles 3–6 and as maintenance monotherapy in cycles 7–34. Palliative radiation to a non-target symptomatic lesion was allowed. The primary objective was overall response rate by RECIST 1.1 criteria. Secondary objectives included safety, progression-free survival, time to progression, duration of response and overall survival. Results: An interim analysis for futility was performed at 18 evaluable patients. Overall response rate was 60%, duration of response was 4.9 months and time to progression was 5.2 months. Progression-free survival at 6 and 12 months was 43% and 5%. Median progression-free survival was 6.2 months and median overall survival was 11.3 months. In all patients, CA125 levels reflected response and progression. There were no pseudoprogression events. After receiving palliative radiation during pembrolizumab maintenance, a patient with recurrent ovarian clear cell carcinoma had an exceptional and durable response that is ongoing for greater than 2 years. After consultation with the sponsor, based on the modest duration of response observed at the interim analysis for futility, the decision was made to close the trial to further accrual. Conclusions: The addition of pembrolizumab to cisplatin and gemcitabine did not appear to provide benefit beyond chemotherapy alone in patients with recurrent platinum-resistant ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Cytochrome P450--inhibiting/inducing Medication Use Among Patients With Advanced Ovarian Cancer (aOC) Who Received or Were Eligible for Poly(ADP-ribose) Polymerase Inhibitors (PARPis) as First-line Maintenance Therapy.
- Author
-
Rimel, Bobbie J., Chase, Dana, Perhanidis, Jessica, Ghazarian, Armen A., Xiaoyan Du, Ella, Wang, Travis, Jinlin Song, Golembesky, Amanda K., Hurteau, Jean A., Salani, Ritu, and Monk, Bradley J.
- Subjects
CYTOCHROME P-450 ,OVARIAN tumors ,ANTINEOPLASTIC agents ,CONFERENCES & conventions ,CANCER patients ,ENZYME inhibitors ,PHARMACODYNAMICS - Abstract
Background: As a class, PARPis work by disrupting DNA repair; however, they are metabolized by different pathways. Niraparib is metabolized by carboxylesterase-catalyzed amide hydrolysis, whereas olaparib and rucaparib are metabolized by the cytochrome P450 (CYP) system. Drugdrug interactions (DDIs) with other medications may change PARPi efficacy or safety in patients with aOC. Objective: This US-based, real-world study aimed to quantify and characterize patients with aOC who received CYP-inhibiting/inducing (CYP-i/i) medications when they initiated treatment or were eligible to receive PARPi first-line maintenance therapy (1LMT), to better understand the potential for DDIs with PARPis and other CYP-metabolized medications. Methods: This retrospective cohort study used data from Optum's de-identified Market Clarity Data with Optum® Enriched Oncology, which deterministically links medical and pharmacy claims with electronic health record data from providers across the continuum of care. Eligible patients were diagnosed with aOC between January 1, 2015, and March 31, 2021; were aged ≥18 years at end of first-line platinum-based chemotherapy (index date); had confirmed CYP-i/i medication use (≥1 claim between 90 days before to 120 days after index date); and had received or were eligible to receive PARPi 1LMT. Strong/moderate CYP-i/i medications were defined based on estimates of how much they increased/decreased drug exposure over time (area under the plasma concentration--time curve ratio). Patients in the PARPi-treated group received PARPi monotherapy for 1LMT (olaparib/rucaparib/niraparib). Patients in the PARPi-eligible group did not receive 1LMT within 120 days or start second-line treatment within 60 days of the index date. Descriptive statistics were used for patient characteristics. Results: The analysis included 1411 patients (PARPi treated, n=158; PARPi eligible, n=1253). Median age was 63 years for PARPi-treated patients and 64 years for PARPi-eligible patients. Among PARPi-treated patients, 46% (n=73) used niraparib, and 54% (n=85) used other PARPis metabolized by the CYP system (olaparib, 49% [n=77]; rucaparib, 5% [n=8]). The percentage of patients taking a strong/ moderate CYP-i/i medication was 38% (n=60) for the overall PARPi-treated group, 42% (n=36) for PARPi-treated patients who received olaparib or rucaparib, and 33% (n=414) for the PARPi-eligible group. For each group, the most common strong/moderate CYP-i/i medications were antiemetics and fluoroquinolone antibiotics (overall PARPi treated, 48% [n=29] and 28% [n=17], respectively; PARPi-treated olaparib/rucaparib, 50% [n=18] and 25% [n=9], respectively; and PARPi eligible, 41% [n=169] and 37% [n=154], respectively). Other common strong/moderate CYP-i/i medications were imidazole-related antifungals, calcium channel--blocking blood pressure medications, and topical antifungals. Conclusions: Patients with aOC may be treated with PARPi 1LMT to delay or prevent recurrence. Multiple PARPi options exist, including niraparib, which is metabolized by carboxylesterase-catalyzed amide hydrolysis, and olaparib and rucaparib, which are metabolized by the CYP system. In this analysis, 38% of PARPi-treated and 33% of PARPi-eligible patients with aOC also received medications that were strong/moderate CYP-i/i. Cotreatment with CYP-metabolized PARPis and CYP-i/i medications could potentially lead to DDIs that could alter the efficacy and tolerability of the PARPis. Additional studies are needed to understand this important issue. Funding: Funding for this study was provided by GSK. [ABSTRACT FROM AUTHOR]
- Published
- 2023
22. Socioeconomic factors do not impact survival in serous borderline ovarian tumors and low grade serous ovarian cancer
- Author
-
Taylor, Kristin N., Li, Andrew John, Rimel, Bobbie J., Walsh, Christine, and Plaxe, Steven Charles
- Published
- 2020
- Full Text
- View/download PDF
23. Obesity is associated with poor clinical outcome in BRCA mutation carriers with epithelial ovarian cancer
- Author
-
John, Catherine, Cass, Ilana, Walsh, Christine, Rimel, Bobbie J., Taylor, Kristin N., and Li, Andrew John
- Published
- 2020
- Full Text
- View/download PDF
24. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- Author
-
Mirza, Mansoor R, Monk, Bradley J, Herrstedt, Jørn, Oza, Amit M, Mahner, Sven, Redondo, Andrés, Fabbro, Michel, Ledermann, Jonathan A, Lorusso, Domenica, Vergote, Ignace, Ben-Baruch, Noa E, Marth, Christian, Madry, Radoslaw, Christensen, René D, Berek, Jonathan S, Dørum, Anne, Tinker, Anna V, du Bois, Andreas, González-Martín, Antonio, Follana, Philippe, Benigno, Benedict, Rosenberg, Per, Gilbert, Lucy, Rimel, Bobbie J, Buscema, Joseph, Balser, John P, Agarwal, Shefali, Matulonis, Ursula A, Lund, Bente, Malander, Susanne, Woie, Kathrine, Hellman, Kristina, Nøttrup, Trine Juhler, Havsteen, Hanne, Sehouli, Jalid, Harter, Philipp, Canzler, Ulrich, Lück, Hans-Joachim, Wölber, Linn, Marmé, Frederik, Meier, Werner, Heubner, Martin, Hilpert, Felix, Emons, Günter, Burges, Alexander, Bover Barcelo, Isabel Maria, Gil Martín, Marta, Palacio Vázquez, Isabel, Casado Herráez, Antonio, Maria del Campo, José, Lesoin, Anne, Berton-Rigaud, Dominique, N'Guyen, Thierry, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lord, Rosemary, Waters, Justin, Montes, Ana, Chan, Stephen, Williams, Sarah J, Barlow, Claire, Mullard, Anna, Colombo, Nicoletta, Scambia, Giovanni, Tognon, Germana, Scollo, Paolo, Kridelka, Frédéric, Leroy, Chantal, Debruyne, Philip, Huizing, Manon, Rosengarten, Ora, Levy, Talia, Frommer, Ronnie Shapira, Fishman, Ami, Edelman, David, Safra, Tamar, Amit, Amnon, Pikiel, Joanna, Suzin, Jacek, Mackowiak-Matejczyk, Beata, Reinthaller, Alexander, Petru, Edgar, Csoszi, Tibor, Bessette, Paul, Provencher, Diane, Lau, Susie, Ellard, Susan, Ghatage, Prafull, Moore, Kathleen, Wenham, Robert, Pineda, Mario, Azodi, Masoud, Mantia-Smaldone, Gina, Cloven, Noelle, Bailey, Cheryl, Lee, Christine, Secord, Angeles, Patel, Manish, Method, Michael, Callahan, Michael, Veena, John, Chan, John, Zarwan, Corrine, DiSilvestro, Paul, Teneriello, Michael, Gupta, Divya, Geller, Melissa, Burris, Howard, Slomovitz, Brian, Hendrickson, Andrea Wahner, McCormick, Colleen, Hanjani, Parviz, Blank, Stephanie, Haluska, Paul, Matei, Daniela, Vasilev, Stephen, Neidhart, Jeffrey, Boente, Matthew, Tchabo, Nana, Miller, David, and Targeted Gynaecologic Oncology (TARGON)
- Subjects
0301 basic medicine ,Oncology ,Medizin ,Genes, BRCA1 ,Platinum Compounds ,POLY(ADP-RIBOSE) POLYMERASE ,Kaplan-Meier Estimate ,030226 pharmacology & pharmacy ,chemistry.chemical_compound ,0302 clinical medicine ,Piperidines ,Maintenance therapy ,Bone Marrow ,Medicine ,Merck Sharp & Dohme ,Homologous Recombination ,Indazoles/adverse effects ,Ovarian Neoplasms ,Aged, 80 and over ,Platinum compounds ,OLAPARIB ,Ovarian Neoplasms/drug therapy ,Obstetrics and Gynecology ,Bone Marrow/drug effects ,General Medicine ,Middle Aged ,SOLID TUMORS ,BRCA MUTATION CARRIERS ,030220 oncology & carcinogenesis ,TRIAL ,Female ,Platinum sensitive ,Adult ,Piperidines/adverse effects ,medicine.medical_specialty ,Indazoles ,Adolescent ,Antineoplastic Agents ,Disease-Free Survival ,Olaparib ,Maintenance Chemotherapy ,Young Adult ,03 medical and health sciences ,Platinum Compounds/therapeutic use ,Double-Blind Method ,Internal medicine ,Humans ,Rucaparib ,Germ-Line Mutation ,Aged ,Neoplasm Staging ,Cancer och onkologi ,business.industry ,Antineoplastic Agents/adverse effects ,NEGATIVE BREAST-CANCER ,030104 developmental biology ,chemistry ,Recurrent Ovarian Cancer ,Cancer and Oncology ,Johnson Johnson ,business - Abstract
BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer. METHODS In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2: 1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival. RESULTS Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo). Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 months vs. 3.8 months in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P amp;lt; 0.001 for all three comparisons). The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications. CONCLUSIONS Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274.) Funding Agencies|Tesaro; Amgen; Genentech; Roche; AstraZeneca; Myriad Genetics; Merck; Gradalis; Cerulean; Vermillion; ImmunoGen; Pfizer; Bayer; Nu-Cana BioMed; INSYS Therapeutics; GlaxoSmithKline; Verastem; Mateon Therapeutics; Pharmaceutical Product Development; Clovis Oncology; Janssen/Johnson Johnson; Eli Lilly; Merck Sharp Dohme
- Published
- 2016
25. The American Society of Clinical Oncology 2017 Annual Meeting: A review and summary of selected abstracts.
- Author
-
Rimel, Bobbie J., Gibson, Steven J., Sumner, Daniele A., and Monk, Bradley J.
- Subjects
- *
CANCER chemotherapy , *LYMPHADENECTOMY , *INTENSIVE care units , *ANTIBIOTICS - Published
- 2017
- Full Text
- View/download PDF
26. The American Society of Clinical Oncology 2016 annual meeting: A review and summary of selected abstracts.
- Author
-
Rimel, Bobbie J., Gibson, Steven J., Sumner, Daniele A., and Monk, Bradley J.
- Subjects
- *
GYNECOLOGIC cancer , *CONFERENCES & conventions - Published
- 2016
- Full Text
- View/download PDF
27. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
- Author
-
Fong, Abigail, Cass, Ilana, John, Catherine, Gillen, Jessica, Moore, Kathleen M., Gangi, Alexandra, Walsh, Christine, Li, Andrew J., Rimel, Bobbie J., Karlan, Beth Y., and Amersi, Farin
- Subjects
- *
BRCA genes , *HEREDITARY cancer syndromes , *OVARIAN cancer , *BREAST cancer , *INSTITUTIONAL review boards , *OVARIAN epithelial cancer , *BREAST tumor diagnosis , *PUBLIC health surveillance , *PROTEINS , *RESEARCH , *GENETIC mutation , *RESEARCH methodology , *RETROSPECTIVE studies , *MAMMOGRAMS , *EVALUATION research , *MEDICAL cooperation , *TUMOR classification , *COMPARATIVE studies , *MASTECTOMY , *BREAST tumors - Abstract
BRCA1 or 2 mutations result in higher cancer risk for breast cancer (BC) and epithelial ovarian cancer (EOC) for carriers than exists in the general population. Optimal breast imaging surveillance in these patients has not been well defined. An Institutional Review Board-approved, multi-institutional retrospective chart review was performed. Patients diagnosed with BRCA-associated EOC between 1990-2015 were identified; demographic and clinical data were collected and analyzed. 192 BRCA mutation-positive patients with EOC were identified. 16/192 (8.3%) women were diagnosed with BC following EOC, at a median of 50 (range 5-327) months following EOC diagnosis and median age 59.5 (45-84) years. Breast cancer was most commonly detected on mammogram 7/16 (44%) or clinical exam 7/16 (44%). 2/16 (12.5%) had occult BC found during risk-reducing mastectomy. 14 (88%) had early-stage (0-2) disease. At mean follow-up of 8.1 years, 6 (37.5%) patients with BC following EOC had died due to EOC. The risk of BC diagnosis following EOC in BRCA mutation carriers is low; most of these BCs are early stage and diagnosed with mammography or physical exam. Overall, survival in BRCA mutation carriers is dominated by EOC-related mortality. Breast cancer surveillance in BRCA mutation carriers following EOC should prioritize nonsurgical strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Epigenetic mismatch repair deficiency in endometrioid endometrial cancer correlates with poor outcome (385).
- Author
-
Kinne, Nolan, Mayer, Christopher, Taylor, Kristin, Manuel, Michael, Rimel, Bobbie, Kim, Kenneth, and Li, Andrew
- Subjects
- *
ENDOMETRIAL cancer , *HEREDITARY nonpolyposis colorectal cancer , *PROGRESSION-free survival , *BODY mass index , *EPIGENETICS , *SURVIVAL rate , *ENDOMETRIAL surgery - Abstract
Objectives: Endometrial cancer due to loss of mismatch repair proteins may be caused by epigenetic or genetic factors. Complete profiling is not routinely performed in clinical practice. We sought to explore outcomes of women with mismatch repair deficiency (MMRd) due to epigenetic MLH-1 promoter hypermethylation (MMRd-MLH). We hypothesize that MMRd-MLH correlates with worse clinical outcomes in endometrial cancer. Methods: Under an IRB protocol, we retrospectively identified patients with endometrioid endometrial adenocarcinoma undergoing hysterectomy at our institution from 2016-2020. These patients underwent routine immunohistochemical testing for MMRd, with subsequent genetic testing or methylation studies for loss of MMR proteins. We examined patient data in three cohorts: MMR proficient (MMRp), MMRd-MLH, and MMRd deficiency due to germline mutation (MMRd-G). We excluded patients who did not undergo MMR testing and those who were MMR deficient due to other causes. We examined clinical data via univariate and multivariate tests and Kaplan-Meier survival analyses. Results: We identified 327 patients who met the criteria for review. The majority (243, 74%) were MMRp, 74 (23%) were MMRd-MLH, and ten (3%) were MMRd-G. On univariate analysis, we observed no differences in the history of post-menopausal hormone replacement therapy, family history of cancer, personal history of hypertension or diabetes mellitus, or body mass index. We found that when compared to the other two groups, MMRd-MLH patients were more like to have grade 2-3 tumors (p < 0.01) and LVSI (p < 0.001). We identified statistically significant associations between age at surgery (60, 67, and 60 years, respectively) and depth of invasion (0.41cm, 0.67cm, and 0.18cm). We did not observe significant differences in the stage. We identified that MMRd-MLH was associated with pathologic high-intermediate risk factors leading to increased adjuvant therapy in stage I disease (p=0.04). We observed a 4.1% recurrence rate in MMRp compared to 8.1% in the MMRd-MLH group compared to no recurrences in MMRd-G (p = NS). When comparing MMRp and MMRd-MLH in Kaplan-Meier analyses, we observed a statistical difference in disease-free survival favoring those who were MMRp (p = 0.02). Median survival was not reached. There were no significant differences in overall survival between MMRp and MMRd-MLH. We did not identify independent prognostic factors for recurrence when controlling for age, stage, grade, or MMR status. [Display omitted] Conclusions: MMRd-MLH is associated with LVSI, higher grade, deeper tumor invasion, and a significantly higher rate of adjuvant therapy. We observed patients with MMRd-MLH were more likely to recur despite adjuvant therapy. MMRd-MLH may represent a poor prognostic factor and a target for further adjuvant therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. A descriptive analysis of posttreatment retention of patients with vulvovaginal dysplasia and malignancies (505).
- Author
-
Mayer, Christopher, Do, Anthony, Cerda, Victoria, Scott, Marla, Rimel, Bobbie, Taylor, Kristin, Li, Andrew, and Kim, Kenneth
- Subjects
- *
VULVAR cancer , *DYSPLASIA , *SQUAMOUS cell carcinoma , *PAP test , *VAGINAL cancer , *SURGICAL excision - Abstract
Objectives: Surveillance follow-up for women with vaginal and vulvar cancer, extrapolated by National Comprehensive Cancer Network (NCCN), includes a physical exam every 3-6 months during the first two years, followed by every 6-12 months for three to five years after treatment. For VAIN, general recommendations for follow-up suggest a physical exam every six months for the first two years and yearly after. For VIN, physical exams every six months for the first five years are recommended. Little is known regarding rates of retention for follow-up in these rare cancers and dysplasia. We sought to explore post-treatment retention for patients with vaginal and vulvar cancer and dysplasia at our institution. Methods: After IRB approval, we retrospectively identified patients treated for vaginal and/or vulvar intraepithelial neoplasia or carcinoma between 2011-2016. Baseline demographic, pathologic, treatment, surveillance, and recurrence data were collected. We examined the continuous and total retention of post-treatment surveillance visits for patients diagnosed with cancer VIN, VAIN, or concomitant VIN and VAIN. Continuous retention was defined as sequential visits no longer than one year apart. Descriptive statistics were used to analyze the data. Results: We identified 40 patients who met the criteria for review. The median age of treatment was 60 years old. Most patients were White (75%), followed by Asian (10%), Black (5%), other (8%), and American Indian (3%). The most common diagnoses were VIN III (25%), VAIN III (22%), and squamous cell carcinoma (22%). Most were treated with wide local excision (42.5%), followed by radical surgery (30%), and laser surgery (15%). The median times for total and continuous post-treatment retention were 27.5 and 21 months, respectively. The median number of visits and pap smears in the first post-treatment year were 2 and 1, respectively. The median number of visits and pap smears in the second post-treatment year were 1 and 1, respectively. Only 29% of patients continued with surveillance in the third post-treatment year. Recurrence was noted in ten patients (25%) with a median time of recurrence of 29 months with a range of 1-69 months. The most common primary diagnoses associated with recurrence were VIN III (40%), VAIN III (20%), VIN II (20%), and squamous cell carcinoma (20%). Conclusions: This is the first baseline assessment of post-treatment surveillance retention for VAIN, VIN, or vulvovaginal carcinoma. We observed that our population generally adheres to NCCN surveillance guidelines during the first year; however, the adherence drops in the following years with a median continuous retention rate of less than two years. Further work is needed to enhance post-treatment surveillance and identify barriers to follow-up for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. P10 Epigenetic mismatch repair deficiency in endometrioid endometrial cancer correlates with poor outcome.
- Author
-
Kinne, Nolan, Mayer, Chrisotpher, Taylor, Kristin, Manuel, Michael, Rimel, Bobbie, Kim, Kenneth, and Li, Andrew
- Subjects
- *
ENDOMETRIAL cancer , *EPIGENETICS - Published
- 2022
- Full Text
- View/download PDF
31. Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects.
- Author
-
Mirza MR, Lindahl G, Mahner S, Redondo A, Fabbro M, Rimel BJ, Herrstedt J, Oza AM, Canzler U, Berek JS, González-Martín A, Follana P, Lord R, Azodi M, Estenson K, Wang Z, Li Y, Gupta D, Matulonis U, and Feng B
- Subjects
- Humans, Female, Recombinational DNA Repair genetics, Retrospective Studies, Neoplasm Recurrence, Local drug therapy, Carcinoma, Ovarian Epithelial drug therapy, Ovarian Neoplasms drug therapy
- Abstract
In this analysis, we examined the relationship between progression-free survival (PFS) and mutation status of 18 homologous recombination repair (HRR) genes in patients in the non-germline BRCA -mutated (non-g BRCA m) cohort of the ENGOT-OV16/NOVA trial (NCT01847274), which evaluated niraparib maintenance therapy for patients with recurrent ovarian cancer. This post hoc exploratory biomarker analysis was performed using tumor samples collected from 331 patients enrolled in the phase III ENGOT-OV16/NOVA trial's non-g BRCA m cohort. Niraparib demonstrated PFS benefit in patients with either somatic BRCA- mutated (s BRCA m; HR, 0.27; 95% confidence interval, CI, 0.08-0.88) or BRCA wild-type ( BRCA wt; HR, 0.47; 95% CI, 0.34-0.64) tumors. Patients with BRCA wt tumors with other non- BRCA HRR mutations also derived benefit from niraparib (HR, 0.31; 95% CI, 0.13-0.77), as did patients with BRCA wt/HRRwt (HRR wild-type) tumors (HR, 0.49; 95% CI, 0.35-0.70). When patients with BRCA wt/HRRwt tumors were further categorized by genomic instability score (GIS), clinical benefit was observed in patients with homologous recombination-deficient (GIS ≥ 42; HR, 0.33; 95% CI, 0.18-0.61) and in patients with homologous recombination-proficient (HRp; GIS < 42; HR, 0.60; 95% CI, 0.36-0.99) disease. Although patients with s BRCA m, other non- BRCA HRR mutations, or GIS ≥ 42 benefited the most from niraparib treatment, PFS benefit was also seen in HRp (GIS < 42) patients without HRR mutations. These results support the use of niraparib in patients with recurrent ovarian cancer regardless of BRCA /HRR mutation status or myChoice CDx GIS., Significance: We retrospectively evaluated the mutational profile of HRR genes in tumor samples from 331 patients from the non-germline BRCA -mutated cohort of the phase III NOVA trial of patients with platinum-sensitive high-grade serous ovarian cancer. Patients with non- BRCA HRR mutations generally benefited from second-line maintenance treatment with niraparib compared with placebo., Competing Interests: G. Lindahl reports personal fees from Honoraria for lectures outside the submitted work. S. Mahner reports grants, personal fees, and other from AbbVie, AstraZeneca, Clovis, Eisai, GSK, Hubro, Medac, MSD, Novartis, Nykode, Olympus, PharmaMar, Pfizer, Roche, Sensor Kinesis, Teva, and Tesaro outside the submitted work. A. Redondo reports personal fees from GSK, MSD; personal fees and other from AstraZeneca; other from Clovis; grants and personal fees from Pharmamar; and grants from Eisai outside the submitted work. M. Fabbro reports personal fees from GSK and AstraZeneca outside the submitted work. B.J. Rimel reports other from GSK, Merck, Immunogen, and personal fees from Deep6AI outside the submitted work. A.M. Oza reports PI and Steering Committees with AstraZeneca, GSK, and Clovis; advisory Board member with AstraZeneca and Morphosys. U. Canzler reports personal fees from AstraZeneca, Lilly, and Roche outside the submitted work. J.S. Berek reports grants from Tesaro during the conduct of the study. A. González-Martín reports personal fees from Alkermes, Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, Merck Sharp & Dohme, MacroGenics, Novartis, Oncoinvent, Pfizer/Merck, PharmaMar, Roche, Sotio, Sutro and grants from GSK and Roche outside the submitted work. P. Follana reports personal fees from GSK, AstraZeneca, and Clovis outside the submitted work. R. Lord reports personal fees from GSK outside the submitted work. Z. Wang reports other from GSK during the conduct of the study; other from GSK outside the submitted work. D. Gupta reports other from GSK during the conduct of the study; other from GSK outside the submitted work; and D. Gupta is an employee of GSK which sponsored the NOVA trial. U. Matulonis reports personal fees from GSK, AstraZeneca, Merck, Novartis, Next Cure, Agenus, 2X oncology, Symphogen, Alkermes, and Morphosys during the conduct of the study; personal fees from Clearity Foundation and Ovarian Cancer Research Alliance outside the submitted work. B. Feng is an employee of GSK. No disclosures were reported by the other authors., (© 2022 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
32. Ovarian Transposition Before Pelvic Radiation Therapy: Spatial Distribution and Dose Volume Analysis.
- Author
-
Gay C, Raphael YR, Steers J, Lu DJ, Lewis JH, DeMarco J, Fraass B, Rimel BJ, Zakariaee R, Kamrava M, and Atkins KM
- Abstract
Purpose: There is a paucity of data analyzing the anatomic locations and dose volume metrics achieved for surgically transposed ovaries in patients desiring fertility or hormonal preservation receiving pelvic radiation therapy (RT), which were examined herein., Methods and Materials: This is a retrospective study including women who underwent ovarian transposition before pelvic RT between 2010 to 2020. The craniocaudal (CC) distance of the ovary centroid to the (1) plane of the sacral promontory, (2) iliac crest, and (3) the nearest distance between the ovary edge and RT planning target volume (PTV) were measured (cm). The area under the receiver operating characteristic curve and cut-point analysis estimating ovary location outside the PTV was performed., Results: Thirty-one ovaries were analyzed from 18 patients. Thirteen (72.2%) were treated with intensity modulated RT, and 5 (27.8%) were treated with 3-dimensional conformal radiation therapy. Most ovaries were located above the sacral promontory (64.5%, n = 20), below the iliac crest (96.8%, n = 30), and outside the PTV (64.5%, n = 20). The median distance from the ovaries to the sacral promontory, iliac crest, and PTV was 0.8 cm (interquartile range [IQR], -0.83 to 1.59 cm), -3.22 cm (IQR, -5.12 to -1.84 cm), and 0.9 cm (IQR, -1.0 to 1.9 cm), respectively. The area under the receiver operating characteristic curve and cut-point analysis demonstrated that distance from the iliac crest predicted an ovary to be outside the PTV with an optimal cut-point of -3.0 cm (C-index = 0.82). The median mean and maximum (Dmax) ovary doses were 15.5 Gy (IQR, 9.6-20.2 Gy) and 32.2 Gy (IQR 24.8-46.5 Gy), respectively., Conclusions: Despite most transposed ovaries being located outside the PTV, nearly all remained below the iliac crest and received RT doses associated with a high risk of ovarian failure. These findings deepen our understanding of the spatial relationship between transposed ovaries and dose to inform surgical and pre-RT planning and suggest that more aggressive ovary-sparing strategies are warranted., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
33. Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination.
- Author
-
Aryal NK, Pant V, Wasylishen AR, Rimel BJ, Baseler L, El-Naggar AK, Mutch DG, Goodfellow PJ, Arur S, and Lozano G
- Subjects
- Animals, Disease Models, Animal, Disease Progression, MAP Kinase Signaling System genetics, Mice, Mice, Inbred C57BL, Neoplasm Invasiveness genetics, Neoplasm Invasiveness pathology, Phosphorylation genetics, Signal Transduction genetics, Carcinogenesis genetics, DEAD-box RNA Helicases genetics, Neoplasms genetics, Neoplasms pathology, Ribonuclease III genetics
- Abstract
Dicer1 functions as a tumor suppressor in mouse models. In humans, somatic mutations are associated with many cancers in adults, and patients with DICER1 syndrome with DICER1 germline mutations are susceptible to childhood cancers. Dicer is phosphorylated by the ERK-MAP kinase pathway and because this pathway is activated in human cancers, we asked whether phosphorylated Dicer1 contributed to tumor development. In human endometrioid cancers, we discovered that phosphorylated DICER1 is significantly associated with invasive disease. To test a direct involvement of Dicer1 phosphorylation in tumor development, we studied mice with phosphomimetic alterations at the two conserved serines phosphorylated by ERK and discovered that a phosphomimetic Dicer1 drives tumor development and dissemination in two independent murine cancer models ( KRas
+/LA1 and p53+/- ). Our findings demonstrate that phosphomimetic Dicer1 promotes tumor development and invasion. SIGNIFICANCE: This work highlights the relevance of Dicer1 phosphorylation in mammalian tumor development and dissemination., (©2019 American Association for Cancer Research.)- Published
- 2019
- Full Text
- View/download PDF
34. Trends and outcomes of women with synchronous endometrial and ovarian cancer.
- Author
-
Matsuo K, Machida H, Blake EA, Holman LL, Rimel BJ, Roman LD, and Wright JD
- Abstract
This retrospective observational study examined trends, characteristics, and survival of women with synchronous endometrial and ovarian cancer (SEOC) in the Surveillance, Epidemiology, and End Results Program between 1973 and 2013. Among 235,454 women with primary endometrial cancer, synchronous ovarian cancer was seen in 4,082 (1.7%) women with the proportion being decreased from 2.0% to 1.6% between 1983 and 2013 ( P =0.049); and the proportion of concurrent endometrioid tumors in the two cancer sites has increased from 24.2% to 49.9% among SEOC women ( P <0.001). When compared to endometrial cancer without synchronous ovarian cancer, endometrioid histology in the two cancer sites was associated with improved cause-specific survival while non-endometrioid histology in the ovarian cancer was associated with decreased cause-specific survival (adjusted- P <0.01). Among 110,063 women with primary epithelial ovarian cancer, synchronous endometrial cancer was seen in 3,940 (3.6%) women with the proportion being increased from 2.2% to 4.4% between 1973 and 2013 ( P <0.001); and the proportion of concurrent endometrioid tumors in the two cancer sites had increased from 24.3% to 50.2% among SEOC women ( P <0.001). When compared to primary epithelial ovarian cancer without synchronous endometrial cancer, SEOC was associated with better cause-specific survival if ovarian cancer is endometrioid type or if endometrial cancer is endometrioid type (adjusted- P <0.001). Across the two cohorts, the proportion of SEOC reached to the peak in the late-40 years of age and then decreased significantly ( P <0.001). In conclusion, our study suggests that synchronous ovarian cancer has decreased among endometrial cancer whereas synchronous endometrial cancer has increased among epithelial ovarian cancer., Competing Interests: CONFLICTS OF INTEREST Dr. Wright has served as a consultant for Clovis Oncology and Tesaro. Dr. Rimel has served as a consultant for Tesaro, AstraZeneca, and Genentech. The other authors have nothing to disclose.
- Published
- 2018
- Full Text
- View/download PDF
35. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
- Author
-
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, and Matulonis UA
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Bone Marrow drug effects, Disease-Free Survival, Double-Blind Method, Female, Genes, BRCA1, Germ-Line Mutation, Homologous Recombination, Humans, Indazoles adverse effects, Kaplan-Meier Estimate, Maintenance Chemotherapy, Middle Aged, Neoplasm Staging, Ovarian Neoplasms genetics, Piperidines adverse effects, Platinum Compounds therapeutic use, Young Adult, Antineoplastic Agents therapeutic use, Indazoles therapeutic use, Ovarian Neoplasms drug therapy, Piperidines therapeutic use
- Abstract
Background: Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer., Methods: In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2:1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival., Results: Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo). Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 months vs. 3.8 months in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P<0.001 for all three comparisons). The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications., Conclusions: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274 .).
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.